Biological subtypes of breast cancer: Prognostic and therapeutic implications.

作者: Ozlem Yersal

DOI: 10.5306/WJCO.V5.I3.412

关键词:

摘要: Breast cancer is a heterogeneous complex of diseases, spectrum many subtypes with distinct biological features that lead to differences in response patterns various treatment modalities and clinical outcomes. Traditional classification systems regarding characteristics may have limitations for patient-tailored strategies. Tumors similar pathological presentations different behaviors. Analyses breast new molecular techniques now hold promise the development more accurate tests prediction recurrence. Gene signatures been developed as predictors therapy protein gene products direct roles driving biology behavior cells are potential targets novel therapeutics. The present review summarizes current knowledge biology, focusing on prognostic predictive factors.

参考文章(83)
Rohit Bhargava, Sushil Beriwal, David J. Dabbs, Umut Ozbek, Atilla Soran, Ronald R. Johnson, Adam M. Brufsky, Barry C. Lembersky, Gretchen M. Ahrendt, Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases. Cancer. ,vol. 116, pp. 1431- 1439 ,(2010) , 10.1002/CNCR.24876
Christopher J. Barnes, Rakesh Kumar, Biology of the epidermal growth factor receptor family. Cancer treatment and research. ,vol. 119, pp. 1- 13 ,(2004) , 10.1007/1-4020-7847-1_1
Sarah Sherlock, Zhuang Liu, Qizhen Cao, Hongjie Dai, Xiaoyuan Chen, Corrine Davis, Kai Chen, Drug delivery with carbon nanotubes for in vivo cancer treatment arXiv: Materials Science. ,(2008) , 10.1158/0008-5472
Zhiyuan Hu, Cheng Fan, Daniel S Oh, JS Marron, Xiaping He, Bahjat F Qaqish, Chad Livasy, Lisa A Carey, Evangeline Reynolds, Lynn Dressler, Andrew Nobel, Joel Parker, Matthew G Ewend, Lynda R Sawyer, Junyuan Wu, Yudong Liu, Rita Nanda, Maria Tretiakova, Alejandra Ruiz Orrico, Donna Dreher, Juan P Palazzo, Laurent Perreard, Edward Nelson, Mary Mone, Heidi Hansen, Michael Mullins, John F Quackenbush, Matthew J Ellis, Olufunmilayo I Olopade, Philip S Bernard, Charles M Perou, The molecular portraits of breast tumors are conserved across microarray platforms BMC Genomics. ,vol. 7, pp. 96- 96 ,(2006) , 10.1186/1471-2164-7-96
Andrew R Green, Emad A Rakha, Ian O Ellis, Hany O Habashy, Desmond G Powe, Tarek M Abdel-Fatah, Julia M W Gee, Robert I Nicholson, A review of the biological and clinical characteristics of luminal‐like oestrogen receptor‐positive breast cancer Histopathology. ,vol. 60, pp. 854- 863 ,(2012) , 10.1111/J.1365-2559.2011.03912.X
Rachel Schiff, Carolina Gutierrez, HER2: biology, detection, and clinical implications. Archives of Pathology & Laboratory Medicine. ,vol. 135, pp. 55- 62 ,(2011) , 10.1043/2010-0454-RAR.1
Florian Heitz, Philipp Harter, Hans-Joachim Lueck, Annette Fissler-Eckhoff, Fatemeh Lorenz-Salehi, Stefanie Scheil-Bertram, Alexander Traut, Andreas du Bois, Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases European Journal of Cancer. ,vol. 45, pp. 2792- 2798 ,(2009) , 10.1016/J.EJCA.2009.06.027
Anna Tessari, Serena Di Cosimo, Dario Palmieri, Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients. Pharmacogenomics and Personalized Medicine. ,vol. 7, pp. 1- 19 ,(2013) , 10.2147/PGPM.S53304
J. Parker, A. Prat, M. Cheang, M. Lenburg, S. Paik, C. Perou, Breast Cancer Molecular Subtypes Predict Response to Anthracycline/Taxane-Based Chemotherapy. Cancer Research. ,vol. 69, pp. 2019- 2019 ,(2009) , 10.1158/0008-5472.SABCS-09-2019